Abstract
Radioimmunotherapy (RIT) using radiolabeled monoclonal antibodies (MAbs) directed against tumor-associated antigens has evolved from an appealing concept to one of the standard treatment options for patients with non-Hodgkins lymphoma (NHL). Inefficient localization of radiolabeled MAbs to nonhematological cancers due to various tumor-related factors, however, limits the therapeutic efficacy of RIT in solid tumors. Still, small volume or minimal residual disease has been recognized as a potentially suitable target for radiolabeled antibodies. Several strategies are being explored aimed at improving the targeting of radiolabeled MAbs to solid tumors thus improving their therapeutic efficacy. In this review, various aspects of the application of radiolabeled MAbs as anti-cancer agents are discussed, and the clinical results of RIT in patients with hematological and various solid cancers (colorectal, ovarian, breast and renal carcinomas) are reviewed.
Keywords: renal cell cancer, colorectal cancer, G250, CD20, carcinoembryonic antigen, Non-Hodgkin's lymphoma, radionuclide, monoclonal antibodies, Radioimmunotherapy
Anti-Cancer Agents in Medicinal Chemistry
Title: Radionuclide Therapy of Cancer with Radiolabeled Antibodies
Volume: 7 Issue: 3
Author(s): Wim J. Oyen, E. J. Postema, Frans H. Corstens, Otto C. Boerman and Manuel J. Koppe
Affiliation:
Keywords: renal cell cancer, colorectal cancer, G250, CD20, carcinoembryonic antigen, Non-Hodgkin's lymphoma, radionuclide, monoclonal antibodies, Radioimmunotherapy
Abstract: Radioimmunotherapy (RIT) using radiolabeled monoclonal antibodies (MAbs) directed against tumor-associated antigens has evolved from an appealing concept to one of the standard treatment options for patients with non-Hodgkins lymphoma (NHL). Inefficient localization of radiolabeled MAbs to nonhematological cancers due to various tumor-related factors, however, limits the therapeutic efficacy of RIT in solid tumors. Still, small volume or minimal residual disease has been recognized as a potentially suitable target for radiolabeled antibodies. Several strategies are being explored aimed at improving the targeting of radiolabeled MAbs to solid tumors thus improving their therapeutic efficacy. In this review, various aspects of the application of radiolabeled MAbs as anti-cancer agents are discussed, and the clinical results of RIT in patients with hematological and various solid cancers (colorectal, ovarian, breast and renal carcinomas) are reviewed.
Export Options
About this article
Cite this article as:
Oyen J. Wim, Postema J. E., Corstens H. Frans, Boerman C. Otto and Koppe J. Manuel, Radionuclide Therapy of Cancer with Radiolabeled Antibodies, Anti-Cancer Agents in Medicinal Chemistry 2007; 7 (3) . https://dx.doi.org/10.2174/187152007780618126
DOI https://dx.doi.org/10.2174/187152007780618126 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Advances in Therapy for Psoriasis: An Overview of Infliximab, Etanercept, Efalizumab, Alefacept, Adalimumab, Tazarotene, and Pimecrolimus
Current Pharmaceutical Design Dibenzofurans from Lichens – A Pharmacological Overview
Current Topics in Medicinal Chemistry Platinum Compounds: A Hope for Future Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Discriminating Ramos and Jurkat Cells with Image Textures from Diffraction Imaging Flow Cytometry Based on a Support Vector Machine
Current Bioinformatics Acetylenic Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Triggering PIK3CA Mutations in PI3K/Akt/mTOR Axis: Exploration of Newer Inhibitors and Rational Preventive Strategies
Current Pharmaceutical Design Natural Compounds with Proteasome Inhibitory Activity for Cancer Prevention and Treatment
Current Protein & Peptide Science Daunorubicin Metabolism in Leukemic Cells Isolated from Patients with Acute Myeloid Leukemia
Drug Metabolism Letters Angiotensin Peptides and Lung Cancer
Current Cancer Drug Targets Synthesis and Biomedical Applications of Dendrimers
Current Organic Chemistry The Role of YY1 in Oncogenesis and Its Potential as a Drug Target in Cancer Therapies
Current Cancer Drug Targets The Dark Side of Stem Cells: Triggering Cancer Progression by Cell Fusion
Current Molecular Medicine The HLA Region and Autoimmune Disease: Associations and Mechanisms of Action
Current Genomics Microfilament Actin Remodeling as a Potential Target for Cancer Drug Development
Current Cancer Drug Targets Glycoconjugates in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Targeting Apoptotic Signaling Pathways in Human Lung Cancer
Current Cancer Drug Targets Self-Emulsifying Lipid Formulation: An Overview
Current Drug Delivery BCR-ABL Inhibitors in Chronic Myeloid Leukemia: Process Chemistry and Biochemical Profile
Current Medicinal Chemistry Phenotypic Alteration of Bone Marrow HSC and Microenvironmental Association in Experimentally Induced Leukemia
Current Stem Cell Research & Therapy The Changing Face of HDAC Inhibitor Depsipeptide
Current Cancer Drug Targets